Luca del Gobbo, delegate for University, research and Open innovation at the Lombardy Region, signed the research agreement with Promidis srl to develop innovative drugs to fight and win the hepatitis B virus. Partners in the project are Istituto Nazionale di Genetica Molecolare-INGM, San Raffaele hospital, Univerity of Milano and Policlicnico “San Matteo” in Pavia. The total funding of the project is 5,6 milions euro.

The project acronyme is CurB. Using cellular systems and models INGM will perform toxicity profiles and antiviral efficacy tests on compounds produced by Promidis Srl (HBV capsid inhibitors), by UniMi (anti-HBV PNA) and will comparatively evaluate MAB and NCE. To this aim, the Virology laboratory of INGM will develop new in vitro infection assays compatible with HTS screening and other assays for specific detection of viral DNA.

More details on “QuotidianoSanità.it” (in Italian)